Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Not Confirmed
Not Confirmed
11-13 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Industry Trade Show
Not Confirmed
11-13 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
07 Aug 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/08/06/2925576/0/en/Aeterna-Zentaris-Inc-Announces-Name-Change-to-COSCIENS-Biopharma-Inc.html
16 Jul 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/07/16/2914159/0/en/Aeterna-Zentaris-Announces-Results-of-Virtual-2024-Meeting-of-Shareholders.html
13 Jun 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/06/13/2898343/0/en/Aeterna-Zentaris-Announces-Last-Patient-Last-Visit-in-Pivotal-DETECT-Trial-for-the-Diagnosis-of-Childhood-Onset-Growth-Hormone-Deficiency.html
03 Jun 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/06/03/2892323/0/en/Aeterna-Zentaris-and-Ceapro-Complete-Merger-Transaction.html
29 May 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/05/29/2890360/0/en/Aeterna-Zentaris-Provides-Update-on-Timing-for-Annual-Meeting-of-Shareholders-and-Due-Bill-Redemption-Date.html
17 May 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/05/17/2884187/0/en/Aeterna-Zentaris-Announces-Details-Regarding-Transaction-with-Ceapro.html
Details:
The combined company will focus on the development of AEZS-130 (macimorelin), a ghrelin receptor agonist and a small molecule that stimulates the secretion of growth hormone from the pituitary gland.
Lead Product(s): Macimorelin
Therapeutic Area: Neurology Brand Name: AEZS-130
Study Phase: PreclinicalProduct Type: Small molecule
Recipient: Ceapro
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger June 03, 2024
Lead Product(s) : Macimorelin
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Recipient : Ceapro
Deal Size : Undisclosed
Deal Type : Merger
Aeterna Zentaris and Ceapro Complete Merger Transaction
Details : The combined company will focus on the development of AEZS-130 (macimorelin), a ghrelin receptor agonist and a small molecule that stimulates the secretion of growth hormone from the pituitary gland.
Brand Name : AEZS-130
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 03, 2024
Details:
The combined company will focus on the development of AEZS-130 (macimorelin), a ghrelin receptor agonist and a small molecule that stimulates the secretion of growth hormone from the pituitary gland.
Lead Product(s): Macimorelin
Therapeutic Area: Neurology Brand Name: AEZS-130
Study Phase: PreclinicalProduct Type: Small molecule
Recipient: Ceapro
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger December 14, 2023
Lead Product(s) : Macimorelin
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Recipient : Ceapro
Deal Size : Undisclosed
Deal Type : Merger
Details : The combined company will focus on the development of AEZS-130 (macimorelin), a ghrelin receptor agonist and a small molecule that stimulates the secretion of growth hormone from the pituitary gland.
Brand Name : AEZS-130
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 14, 2023
Details:
Macimorelin (Macrilen®; GHRYVELIN™), a ghrelin agonist, is an orally active small molecule that stimulates the secretion of growth hormone from the pituitary gland.
Lead Product(s): Macimorelin Acetate
Therapeutic Area: Endocrinology Brand Name: Macrilen
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2023
Lead Product(s) : Macimorelin Acetate
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Macimorelin (Macrilen®; GHRYVELIN™), a ghrelin agonist, is an orally active small molecule that stimulates the secretion of growth hormone from the pituitary gland.
Brand Name : Macrilen
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 05, 2023
Details:
Under the Commercial License, Novo Nordisk was granted an exclusive license for the development, manufacturing, registration and commercialization of Macrilen™ (macimorelin) in the U.S. and Canada.
Lead Product(s): Macimorelin
Therapeutic Area: Endocrinology Brand Name: Macrilen
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Novo Nordisk
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination August 29, 2022
Lead Product(s) : Macimorelin
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Novo Nordisk
Deal Size : Undisclosed
Deal Type : Termination
Aeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from No...
Details : Under the Commercial License, Novo Nordisk was granted an exclusive license for the development, manufacturing, registration and commercialization of Macrilen™ (macimorelin) in the U.S. and Canada.
Brand Name : Macrilen
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 29, 2022
Details:
Preliminary data with mouse 2D2 models of spontaneous autoimmune encephalomyelitis (EAE) indicate that mouse-adapted AIM Biologicals may reduce optic neuritis, loss of inner nuclear layer neurons and EAE symptoms.
Lead Product(s): Autoimmunity Modifying Biologicals
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2022
Lead Product(s) : Autoimmunity Modifying Biologicals
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Aeterna Zentaris Achieves Proof-of-Concept for the Treatment of NMOSD with AIM Biologicals Program
Details : Preliminary data with mouse 2D2 models of spontaneous autoimmune encephalomyelitis (EAE) indicate that mouse-adapted AIM Biologicals may reduce optic neuritis, loss of inner nuclear layer neurons and EAE symptoms.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 13, 2022
Details:
The pre-clinical data presented showed consistent effects in various in-vitro and in-vivo models, verifying the potential of HLA-G based molecules to induce antigen-specific immune-modulation.
Lead Product(s): Autoimmunity Modifying Biologicals
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Large molecule
Sponsor: AIM Biologicals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Lead Product(s) : Autoimmunity Modifying Biologicals
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : AIM Biologicals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The pre-clinical data presented showed consistent effects in various in-vitro and in-vivo models, verifying the potential of HLA-G based molecules to induce antigen-specific immune-modulation.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 12, 2022
Details:
AIM Biologicals utilize a novel mechanism based on peptide antigens that are presented on immunosuppressive MHC class I molecules, to selectively and efficiently induce antigen-specific tolerance.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Aeterna Zentaris Abstract Accepted for Presentation at IMMUNOLOGY2022™, the Annual Event of the ...
Details : AIM Biologicals utilize a novel mechanism based on peptide antigens that are presented on immunosuppressive MHC class I molecules, to selectively and efficiently induce antigen-specific tolerance.
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Not Applicable
April 25, 2022
Details:
Antigen presentation on MHC class Ib-related molecules induces Aquaporin4-specific regulatory T cells in PBMC from NMOSD patients and prevents experimental autoimmune encephalomyelitis in mice.
Lead Product(s): Undisclosed
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Aeterna Zentaris Abstract Accepted for Presentation at 13th International Congress on Autoimmunity
Details : Antigen presentation on MHC class Ib-related molecules induces Aquaporin4-specific regulatory T cells in PBMC from NMOSD patients and prevents experimental autoimmune encephalomyelitis in mice.
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Not Applicable
April 11, 2022
Details:
AEZS-150 (delayed clearance parathyroid hormone fusion polypeptides DC-PTH), a proprietary fusion protein consisting of a modified GHBP linked to parathyroid hormone PTH1-34 with the goal to provide a PTH analog with delayed clearance of one or two weeks.
Lead Product(s): Delayed Clearance Parathyroid Hormone
Therapeutic Area: Endocrinology Brand Name: AEZS-150
Study Phase: PreclinicalProduct Type: Peptide
Sponsor: University of Sheffield
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2022
Lead Product(s) : Delayed Clearance Parathyroid Hormone
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : University of Sheffield
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AEZS-150 (delayed clearance parathyroid hormone fusion polypeptides DC-PTH), a proprietary fusion protein consisting of a modified GHBP linked to parathyroid hormone PTH1-34 with the goal to provide a PTH analog with delayed clearance of one or two weeks...
Brand Name : AEZS-150
Molecule Type : Peptide
Upfront Cash : Not Applicable
March 02, 2022
Details:
The Company intends to use the net proceeds of this offering for general corporate purposes, which includes funding of a pediatric clinical trial in the E.U. and U.S. for Macrilen, the investigation of further therapeutic uses of macimorelin.
Lead Product(s): Macimorelin
Therapeutic Area: Endocrinology Brand Name: Macrilen
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: H.C. Wainwright & Co.
Deal Size: $12.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 01, 2020
Lead Product(s) : Macimorelin
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : H.C. Wainwright & Co.
Deal Size : $12.0 million
Deal Type : Public Offering
Aeterna Zentaris Announces Pricing of $12 Million Public Offering
Details : The Company intends to use the net proceeds of this offering for general corporate purposes, which includes funding of a pediatric clinical trial in the E.U. and U.S. for Macrilen, the investigation of further therapeutic uses of macimorelin.
Brand Name : Macrilen
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 01, 2020
Inspections and registrations
ABOUT THIS PAGE
Aeterna Zentaris is a supplier offers 1 products (APIs, Excipients or Intermediates).
Find a price of Perifosine bulk offered by Aeterna Zentaris
LOOKING FOR A SUPPLIER?